Puglia Locks In the Full Spectrum of Diabetes Technology in a EUR 165 Million Framework, Led by Medtronic and Abbott

Standfirst

InnovaPuglia has awarded a nine-lot framework agreement worth EUR 164 951 360 covering insulin pumps, automated insulin delivery systems and continuous glucose monitors for the Puglia region's diabetes patients. Medtronic and Abbott emerged as the largest winners, each capturing multiple lots across the region's full range of modern diabetes management technology.

Introduction

Managing type 1 diabetes today increasingly means wearing connected technology: an insulin pump that delivers medication automatically, a sensor that tracks blood glucose continuously through the skin and software that links the two together to prevent dangerous highs and lows without constant manual intervention. Puglia's regional health system has just secured that entire technology stack for its patients in one coordinated procurement.

Nine separate lots, each covering a distinct category of insulin delivery or glucose monitoring device, drew bids from essentially every major name in global diabetes technology, Medtronic, Abbott, Roche and Ascensia among them, alongside specialist Italian distributors.

Why This Contract Matters

The range of technology covered here maps closely onto how diabetes care has evolved in recent years: from basic catheter based insulin pumps through to fully automated insulin delivery systems that adjust dosing based on real time glucose readings and from standard continuous glucose monitors to long duration implantable style sensors and simpler flash monitoring systems. Securing all of these categories through a single coordinated regional framework gives Puglia's diabetes patients access to a genuinely comprehensive range of modern treatment options.

The scale involved, close to EUR 165 million, also reflects how central this technology has become to diabetes management and how significant a share of regional healthcare technology budgets now goes toward keeping patients connected to increasingly sophisticated monitoring and delivery devices.

Contract Timeline

• Procedure type: Open procedure
• Notice dispatched to the Publications Office: 3 September 2026
• Published in the Official Journal, OJ S 172/2026: 7 September 2026, as notice version 05

Contract Overview

InnovaPuglia ran an open procedure to conclude a framework agreement for high technology devices for insulin administration and continuous glucose monitoring, split into nine lots by device category. Every lot was evaluated on a combined quality and price basis. The combined estimated value across all nine lots is EUR 164 951 360.

Key Contract Details

Project Scope

The nine lots and their winners are:

About the Contracting Authority

InnovaPuglia S.p.A. is a regional authority based in Puglia, southern Italy, acting as the region's in-house company for coordinating procurement and innovation, including large scale medical technology frameworks for the region's public health system.

About the Organisations Involved

InnovaPuglia S.p.A.

As covered above, InnovaPuglia is the buyer running this framework on behalf of Puglia's regional health system.

TAR Puglia – Bari

The Regional Administrative Court of Puglia, based in Bari, is the review organisation for this contract, with ANAC, Italy's National Anti-Corruption Authority, also listed in a supporting procurement oversight role.

Medtronic Italia SpA

Medtronic, based in Milan, is the broadest winner across this framework, securing five lots spanning insulin micropumps, automated insulin delivery, integrated pump-sensor systems, real-time CGM and injection cannulas. Medtronic is a major global medical technology company well known internationally for its MiniMed insulin pump systems.

Abbott

Abbott won three lots: both real-time CGM categories and the flash glucose monitoring lot, the latter won outright without a co-winner. Abbott is globally recognised for its FreeStyle Libre continuous and flash glucose monitoring systems, one of the most widely used sensor technologies in diabetes care today.

Roche Diabetes Care Italy SpA

Roche Diabetes Care, based in Milan, won two lots covering the patch insulin micropump and real-time CGM without predictive alerts, reflecting its established diabetes care portfolio built around the Accu-Chek brand.

Biochemical Systems International SpA

Biochemical Systems International won three lots: the patch micropump, automated insulin delivery and the integrated pump-sensor category, giving it a broad presence across the insulin delivery side of this framework.

Ascensia Diabetes Care Italy S.r.l.

Ascensia, based in Milan and known internationally for its Contour blood glucose monitoring products, won the long duration subcutaneous CGM lot outright.

B.C.Trade, Movi SpA, mylife Diabetes Care Italia, Pikdare and Theras Biocare

These five companies rounded out the winning field. B.C.Trade won the insulin micropump with catheter and patch micropump lots. Movi and mylife Diabetes Care Italia, the Italian arm of Swiss diabetes technology company Ypsomed, both won places in the automated insulin delivery lot. Pikdare, based in Como, won places across three lots spanning micropumps and both real-time CGM categories. Theras Biocare, based near Parma, won the injection cannula lot alongside Medtronic.

Procurement Analysis

Every lot in this framework was evaluated on a combined quality and price basis, appropriate for medical devices where usability, accuracy and patient safety features matter as much as cost. The multi-winner structure across most lots, particularly the larger CGM and automated insulin delivery categories, gives prescribing clinicians and patients choice among several qualified device options rather than a single mandated product, an important consideration in diabetes technology where individual patient preference and physiology can affect which system works best.

The combined lot values reconcile exactly with the procedure's overall EUR 164 951 360 estimate, a clean, internally consistent notice.

Additional Procurement Facts

• This notice has been revised multiple times, now published as its fifth version.
• The framework covers nine distinct device categories spanning the full range of current insulin delivery and glucose monitoring technology.
• ANAC, Italy's National Anti-Corruption Authority, is listed alongside the regional administrative court in the procurement's oversight structure.

Market and Industry Perspective

This framework offers a comprehensive snapshot of the diabetes technology market as it currently stands, with global leaders Medtronic and Abbott each securing broad, multi-category positions, while Roche, Ascensia and Ypsomed's mylife brand each hold more targeted positions in specific device categories. The presence of several Italian specialist distributors alongside these global names reflects how device distribution in Italian regional healthcare markets often runs through established local intermediaries even for internationally manufactured technology.

Economic Significance

At close to EUR 165 million, this framework represents a substantial regional investment in modern diabetes care technology, giving Puglia's patient population access to automated insulin delivery and advanced continuous glucose monitoring at a scale that reflects the growing clinical importance of these technologies in diabetes management.

Future Procurement Opportunities

As diabetes technology continues to advance, particularly in automated and closed-loop insulin delivery, further framework recompetes are likely once current terms conclude, offering device manufacturers not yet represented here further opportunities to enter this market.

Opportunities for Suppliers

Diabetes technology manufacturers and distributors should note the multi-winner lot structure demonstrated here, which allows several qualified suppliers to compete within the same device category rather than a single winner taking the entire market, a pattern that leaves room for well positioned competitors even in a market with strong established global leaders.

What Businesses Should Watch

• How patient and clinician choice distributes usage across the multiple winning suppliers within each device category.
• Further InnovaPuglia medical technology tenders as the region continues investing in advanced patient care technology.
• Broader adoption trends in automated insulin delivery and continuous glucose monitoring across other Italian regions.

ItalyTenders.com Procurement Intelligence

This framework is a clear illustration of how comprehensively a single coordinated regional tender can cover an entire category of modern medical technology, from basic insulin delivery through to the most advanced automated systems, while still preserving genuine supplier choice within most categories. For diabetes technology manufacturers, competing successfully in this kind of framework increasingly requires either broad category coverage, as Medtronic and Abbott demonstrated, or focused excellence in a specific niche, as Ascensia's standalone win in the long duration CGM category shows.

The involvement of established Italian distributors alongside global device manufacturers also underscores how much regional Italian healthcare procurement still depends on local market knowledge and distribution relationships, even when the underlying technology itself is developed and manufactured by multinational companies.

Supplier Takeaways

• Medtronic and Abbott each secured broad, multi-category positions across this framework, reflecting the value of comprehensive product portfolios in diabetes technology tenders.
• Most lots were awarded to multiple suppliers, preserving genuine choice for clinicians and patients within each device category.
• Standalone category wins, like Ascensia's long duration CGM lot, show that focused specialisation can still secure exclusive market access.
• Award criteria combined quality and price across all nine lots, rewarding device usability and safety features alongside cost.
• Italian specialist distributors continue to play a significant role in this market alongside global device manufacturers.

Key Takeaways

• InnovaPuglia awarded a nine-lot diabetes technology framework worth EUR 164 951 360, covering insulin pumps, automated insulin delivery and continuous glucose monitoring.
• Medtronic Italia won the broadest position, securing five of the nine lots.
• Abbott won three lots including the flash glucose monitoring category outright.
• Roche Diabetes Care, Biochemical Systems International, Ascensia and several Italian distributors also secured lot wins.
• All lots were evaluated on a combined quality and price basis.
• This notice has been revised multiple times, now published as its fifth version.

Conclusion

From a basic insulin cannula to a fully automated closed-loop delivery system, this framework gives Puglia's diabetes patients access to the complete modern toolkit of insulin management technology, sourced from the industry's leading names. With Medtronic and Abbott anchoring the broadest categories and several specialists filling in the rest, the region has built a comprehensive, competitively sourced foundation for diabetes care that should serve its patient population for years to come.

Source: Tenders Electronic Daily (TED), Contract Award Notice 612988 2026, Official Journal of the European Union, OJ S 172/2026, published on 7 September 2026.